JP2017512779A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017512779A5 JP2017512779A5 JP2016557602A JP2016557602A JP2017512779A5 JP 2017512779 A5 JP2017512779 A5 JP 2017512779A5 JP 2016557602 A JP2016557602 A JP 2016557602A JP 2016557602 A JP2016557602 A JP 2016557602A JP 2017512779 A5 JP2017512779 A5 JP 2017512779A5
- Authority
- JP
- Japan
- Prior art keywords
- het
- group
- substituents
- alkyl
- oxo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000001424 substituent group Chemical group 0.000 claims 38
- 150000001875 compounds Chemical class 0.000 claims 24
- -1 Het Chemical group 0.000 claims 23
- 125000004043 oxo group Chemical group O=* 0.000 claims 22
- 229910052736 halogen Inorganic materials 0.000 claims 17
- 150000002367 halogens Chemical class 0.000 claims 17
- 125000001072 heteroaryl group Chemical group 0.000 claims 17
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 14
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 14
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 13
- 150000003839 salts Chemical class 0.000 claims 9
- 125000004093 cyano group Chemical group *C#N 0.000 claims 8
- 125000000753 cycloalkyl group Chemical group 0.000 claims 8
- 229910052757 nitrogen Inorganic materials 0.000 claims 8
- 229910052760 oxygen Inorganic materials 0.000 claims 7
- 229910052717 sulfur Inorganic materials 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 125000005842 heteroatom Chemical group 0.000 claims 6
- 206010025135 lupus erythematosus Diseases 0.000 claims 6
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 5
- 208000010668 atopic eczema Diseases 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 3
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims 3
- 206010012434 Dermatitis allergic Diseases 0.000 claims 3
- 208000005777 Lupus Nephritis Diseases 0.000 claims 3
- 206010039085 Rhinitis allergic Diseases 0.000 claims 3
- 201000010105 allergic rhinitis Diseases 0.000 claims 3
- 208000006673 asthma Diseases 0.000 claims 3
- 201000008937 atopic dermatitis Diseases 0.000 claims 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 2
- 206010012442 Dermatitis contact Diseases 0.000 claims 2
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 2
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 2
- 206010006451 bronchitis Diseases 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 208000010247 contact dermatitis Diseases 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 1
- 125000004343 1-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 208000028185 Angioedema Diseases 0.000 claims 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 208000003950 B-cell lymphoma Diseases 0.000 claims 1
- 206010065687 Bone loss Diseases 0.000 claims 1
- 229940124003 CRTH2 antagonist Drugs 0.000 claims 1
- RRXSYZFVDIRTFB-UHFFFAOYSA-N C[CH]C1=CC=C(OC)C=C1 Chemical group C[CH]C1=CC=C(OC)C=C1 RRXSYZFVDIRTFB-UHFFFAOYSA-N 0.000 claims 1
- 208000015943 Coeliac disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 208000004332 Evans syndrome Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 208000024869 Goodpasture syndrome Diseases 0.000 claims 1
- 206010018690 Granulocytosis Diseases 0.000 claims 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
- 206010018910 Haemolysis Diseases 0.000 claims 1
- 201000004331 Henoch-Schoenlein purpura Diseases 0.000 claims 1
- 206010019617 Henoch-Schonlein purpura Diseases 0.000 claims 1
- 208000031814 IgA Vasculitis Diseases 0.000 claims 1
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims 1
- 206010021263 IgA nephropathy Diseases 0.000 claims 1
- 208000011200 Kawasaki disease Diseases 0.000 claims 1
- 208000034624 Leukocytoclastic Cutaneous Vasculitis Diseases 0.000 claims 1
- 208000032514 Leukocytoclastic vasculitis Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 206010042971 T-cell lymphoma Diseases 0.000 claims 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 208000024780 Urticaria Diseases 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 208000002205 allergic conjunctivitis Diseases 0.000 claims 1
- 230000000172 allergic effect Effects 0.000 claims 1
- 208000007502 anemia Diseases 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 208000024998 atopic conjunctivitis Diseases 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 230000003454 betamimetic effect Effects 0.000 claims 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000000812 cholinergic antagonist Substances 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 229940121647 egfr inhibitor Drugs 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 230000008588 hemolysis Effects 0.000 claims 1
- 208000007475 hemolytic anemia Diseases 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 1
- 201000006362 hypersensitivity vasculitis Diseases 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 208000015446 immunoglobulin a vasculitis Diseases 0.000 claims 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 201000010901 lateral sclerosis Diseases 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 125000002911 monocyclic heterocycle group Chemical group 0.000 claims 1
- 208000005264 motor neuron disease Diseases 0.000 claims 1
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 208000004235 neutropenia Diseases 0.000 claims 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- 230000000010 osteolytic effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 125000000168 pyrrolyl group Chemical group 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- GUSDJDARKXWLBJ-UHFFFAOYSA-N CCBc1cc(O)c2[s]c(C)nc2c1 Chemical compound CCBc1cc(O)c2[s]c(C)nc2c1 GUSDJDARKXWLBJ-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461955487P | 2014-03-19 | 2014-03-19 | |
| US61/955,487 | 2014-03-19 | ||
| PCT/EP2015/055237 WO2015140054A1 (en) | 2014-03-19 | 2015-03-12 | Heteroaryl syk inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017512779A JP2017512779A (ja) | 2017-05-25 |
| JP2017512779A5 true JP2017512779A5 (enExample) | 2018-04-12 |
| JP6535022B2 JP6535022B2 (ja) | 2019-06-26 |
Family
ID=52706148
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016557587A Active JP6599884B2 (ja) | 2014-03-19 | 2015-03-12 | 新規なヘテロアリール化合物及び医薬としてのその使用 |
| JP2016557602A Active JP6535022B2 (ja) | 2014-03-19 | 2015-03-12 | ヘテロアリールｓｙｋ阻害剤 |
| JP2016557952A Active JP6416275B2 (ja) | 2014-03-19 | 2015-03-12 | ヘテロアリールｓｙｋ阻害剤 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016557587A Active JP6599884B2 (ja) | 2014-03-19 | 2015-03-12 | 新規なヘテロアリール化合物及び医薬としてのその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016557952A Active JP6416275B2 (ja) | 2014-03-19 | 2015-03-12 | ヘテロアリールｓｙｋ阻害剤 |
Country Status (32)
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3119766B1 (en) | 2014-03-19 | 2019-05-22 | Boehringer Ingelheim International GmbH | Heteroaryl syk inhibitors |
| EP3347353B1 (en) * | 2015-09-11 | 2019-07-17 | Boehringer Ingelheim International GmbH | Pyrazolyl-substituted heteroaryls and their use as medicaments |
| SG11201803605YA (en) * | 2015-11-02 | 2018-05-30 | Janssen Pharmaceutica Nv | [1,2,4]TRIAZOLO[1,5-a]PYRIMIDIN-7-YL COMPOUND |
| CN105503730B (zh) * | 2015-12-25 | 2018-06-22 | 山东大学 | 吡唑类衍生物及其制备方法与应用 |
| BR112019008604A2 (pt) | 2016-11-02 | 2019-07-09 | Janssen Pharmaceutica Nv | compostos de [1,2,4]triazolo[1,5-a]pirimidina como inibidores de pde2 |
| MX385576B (es) * | 2016-11-02 | 2025-03-18 | Janssen Pharmaceutica Nv | Derivados de [1,2,4]triazol[1,5-a]pirimidina como inhibidores de pde2 |
| CN109937202B (zh) | 2016-11-02 | 2022-12-30 | 詹森药业有限公司 | 作为pde2抑制剂的[1,2,4]三唑并[1,5-a]嘧啶化合物 |
| MA47106A (fr) | 2016-12-21 | 2019-10-30 | Amgen Inc | Formulations d'anticorps anti-tnf alpha |
| CN111108105B (zh) | 2017-09-22 | 2023-03-31 | 朱比兰特埃皮帕德有限公司 | 作为pad抑制剂的杂环化合物 |
| KR102782563B1 (ko) | 2017-10-18 | 2025-03-14 | 주빌런트 에피파드 엘엘씨 | Pad 억제제로서의 이미다조-피리딘 화합물 |
| AU2018362046B2 (en) | 2017-11-06 | 2023-04-13 | Jubilant Prodel LLC | Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation |
| HUE067265T2 (hu) | 2017-11-24 | 2024-10-28 | Jubilant Episcribe Llc | Heterociklusos vegyületek mint PRMT5 inhibitorok |
| IL315310A (en) | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| EP3765453A1 (en) | 2018-03-13 | 2021-01-20 | Jubilant Prodel LLC | Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation |
| EP3817822A4 (en) | 2018-07-06 | 2022-07-27 | Kymera Therapeutics, Inc. | PROTEIN DEGRADANTS AND USES THEREOF |
| CA3117556A1 (en) | 2018-10-31 | 2020-05-07 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds as hpk1 inhibitors |
| TWI721624B (zh) | 2018-10-31 | 2021-03-11 | 美商基利科學股份有限公司 | 經取代之6-氮雜苯并咪唑化合物 |
| SG11202105424PA (en) | 2018-11-30 | 2021-06-29 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| US11633399B2 (en) | 2018-12-25 | 2023-04-25 | Sol-Gel Technologies Ltd. | Treatment of skin disorders with compositions comprising an EGFR inhibitor |
| AU2020242287A1 (en) | 2019-03-21 | 2021-09-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A Dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| EP3972695A1 (en) | 2019-05-23 | 2022-03-30 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
| US20230089916A1 (en) * | 2019-06-28 | 2023-03-23 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| KR20220098759A (ko) | 2019-11-08 | 2022-07-12 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 키나제 억제제에 대해 내성을 획득한 암의 치료 방법 |
| MX2022007576A (es) | 2019-12-17 | 2022-09-23 | Kymera Therapeutics Inc | Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos. |
| EP4076524A4 (en) | 2019-12-17 | 2023-11-29 | Kymera Therapeutics, Inc. | IRAQ DEGRADERS AND USES THEREOF |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| TW202210483A (zh) | 2020-06-03 | 2022-03-16 | 美商凱麥拉醫療公司 | Irak降解劑之結晶型 |
| US20220213086A1 (en) * | 2020-12-25 | 2022-07-07 | Eternity Bioscience Inc. | Azole compounds as irak inhibitors, preparation methods and medicinal uses thereof |
| AU2021413371A1 (en) | 2020-12-30 | 2023-07-13 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| AU2022220043A1 (en) | 2021-02-15 | 2023-08-31 | Kymera Therapeutics, Inc. | Irak4 degraders and uses thereof |
| KR20220138654A (ko) * | 2021-04-06 | 2022-10-13 | 주식회사 온코크로스 | 당뇨병의 예방 또는 치료용 화합물 |
| KR20220138655A (ko) * | 2021-04-06 | 2022-10-13 | 주식회사 온코크로스 | 신장 질환의 예방 또는 치료용 화합물 |
| CN118302168A (zh) | 2021-10-29 | 2024-07-05 | 凯麦拉医疗公司 | Irak4降解剂和其制备 |
| EP4472967A2 (en) | 2022-01-31 | 2024-12-11 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| CN115215803B (zh) * | 2022-09-19 | 2022-12-30 | 苏州美诺医药科技有限公司 | 一种4-卤代-1-(二氟甲基)-1h-咪唑的制备方法 |
| WO2024081889A1 (en) | 2022-10-14 | 2024-04-18 | Genesis Therapeutics, Inc. | 4h-pyrido[1,2-a]pyrimidin-4-one derivatives for treating cancer |
| CN116836162B (zh) * | 2023-05-24 | 2025-09-05 | 南方医科大学 | 吡唑[4,3-c]吡啶类化合物或其药学上可接受的盐及其应用 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4260759A (en) | 1969-04-14 | 1981-04-07 | Schering-Corporation | Process for preparing 1-aminonaphthyridines |
| US3928367A (en) | 1969-04-14 | 1975-12-23 | Schering Corp | 1-Amino naphthyridines |
| US4017500A (en) | 1973-07-16 | 1977-04-12 | Schering Corporation | Certain 8-amino-1,7-naphthyridines |
| FR2260330A1 (en) | 1974-02-07 | 1975-09-05 | Innothera Lab Sa | Pyridoxine N-oxy nicotinate - hypolipaemiant and hypocholesterolemiant of good therapeutic index |
| US4115395A (en) | 1975-11-12 | 1978-09-19 | Schering Corporation | 1-Aminonaphthyridines |
| EP1020445B1 (en) | 1997-10-02 | 2008-08-13 | Eisai R&D Management Co., Ltd. | Fused pyridine derivatives |
| AU2001229501A1 (en) | 2000-01-24 | 2001-07-31 | Isis Pharmaceuticals, Inc. | Antisense modulation of inducible nitric oxide synthase expression |
| GB0004153D0 (en) | 2000-02-23 | 2000-04-12 | Astrazeneca Uk Ltd | Novel use |
| JP2001302667A (ja) * | 2000-04-28 | 2001-10-31 | Bayer Ag | イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体 |
| CA2425539C (en) | 2000-10-12 | 2007-04-03 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Crystalline monohydrate, processes for the preparation thereof and the use thereof for preparing a pharmaceutical composition |
| AR035700A1 (es) | 2001-05-08 | 2004-06-23 | Astrazeneca Ab | Derivados de arilheteroalquilamina, composicion farmaceutica, usos de estos derivados para la fabricacion de medicamentos, metodos de tratamiento, y proceso para la preparacion de estos derivados |
| ES2271280T3 (es) | 2001-06-22 | 2007-04-16 | BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG | Anticolinergico cristalino, procedimiento para su preparacion y su uso para la produccion de un medicamento. |
| US20030158195A1 (en) | 2001-12-21 | 2003-08-21 | Cywin Charles L. | 1,6 naphthyridines useful as inhibitors of SYK kinase |
| SE0203304D0 (sv) | 2002-11-07 | 2002-11-07 | Astrazeneca Ab | Novel Coumpounds |
| CN1784229A (zh) * | 2003-03-10 | 2006-06-07 | 先灵公司 | 杂环激酶抑制剂:使用方法与合成 |
| US20080119515A1 (en) | 2003-03-10 | 2008-05-22 | M Arshad Siddiqui | Heterocyclic Kinase Inhibitors: Methods of Use and Synthesis |
| WO2006038041A1 (en) | 2004-10-08 | 2006-04-13 | Merck Sharp & Dohme Limited | Besylate salts of six-membered amino-heterocycles as vanilloid-1 receptor antagonists for treating pain |
| WO2007144785A2 (en) * | 2006-03-26 | 2007-12-21 | Uti Limited Partnership | Ryanodine receptor inhibitors and methods relating thereto |
| DE102007012645A1 (de) | 2007-03-16 | 2008-09-18 | Bayer Healthcare Ag | Substituierte Imidazo- und Triazolopyrimidine |
| WO2010015518A2 (de) | 2008-08-05 | 2010-02-11 | Boehringer Ingelheim Interntional Gmbh | 4-dimethylamino-phenyl-substituierte naphthyridine und ihre verwendung als arzneimittel |
| WO2010015520A1 (de) | 2008-08-05 | 2010-02-11 | Boehringer Ingelheim International Gmbh | Substituierte naphthyridine und ihre verwendung als arzneimittel |
| TWI453207B (zh) * | 2008-09-08 | 2014-09-21 | Signal Pharm Llc | 胺基三唑并吡啶，其組合物及使用其之治療方法 |
| EA201201052A1 (ru) | 2010-01-29 | 2013-02-28 | Бёрингер Ингельхайм Интернациональ Гмбх | Замещенные нафтиридины и их применение в качестве ингибиторов киназы syk |
| US20140005188A1 (en) | 2011-03-11 | 2014-01-02 | Glaxo Group Limited | Pyrido[3,4-b]pyrazine derivatives as syk inhibitors |
| JP6001048B2 (ja) | 2011-03-28 | 2016-10-05 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | チアゾロピリミジン化合物 |
| WO2012167423A1 (en) | 2011-06-08 | 2012-12-13 | Hutchison Medipharma Limited | Substituted pyridopyrazines as novel syk inhibitors |
| PH12014500209A1 (en) | 2011-07-26 | 2014-03-03 | Boehringer Ingelheim Int | Substituted quinolines and their use as medicaments |
| JP5878178B2 (ja) * | 2011-09-30 | 2016-03-08 | 大鵬薬品工業株式会社 | １，２，４−トリアジン−６−カルボキサミド誘導体 |
| CA2874546A1 (en) * | 2012-06-07 | 2013-12-12 | F. Hoffmann-La Roche Ag | Pyrazolopyrimidone and pyrazolopyridone inhibitors of tankyrase |
| WO2014100113A2 (en) | 2012-12-18 | 2014-06-26 | Hulow, Llc | Syk kinase inhibitors as treatment for malaria |
| AU2014296184B2 (en) * | 2013-07-31 | 2017-04-27 | Gilead Sciences, Inc. | Syk inhibitors |
| EP3119766B1 (en) | 2014-03-19 | 2019-05-22 | Boehringer Ingelheim International GmbH | Heteroaryl syk inhibitors |
| TW201617074A (zh) | 2014-07-14 | 2016-05-16 | 吉李德科學股份有限公司 | Ｓｙｋ（脾酪胺酸激酶）抑制劑 |
| EP3347353B1 (en) | 2015-09-11 | 2019-07-17 | Boehringer Ingelheim International GmbH | Pyrazolyl-substituted heteroaryls and their use as medicaments |
-
2015
- 2015-03-12 EP EP15711453.9A patent/EP3119766B1/en active Active
- 2015-03-12 JP JP2016557587A patent/JP6599884B2/ja active Active
- 2015-03-12 EA EA201691864A patent/EA032097B1/ru not_active IP Right Cessation
- 2015-03-12 CN CN201580013694.5A patent/CN106255689B/zh active Active
- 2015-03-12 CA CA2942997A patent/CA2942997C/en active Active
- 2015-03-12 CN CN201910890873.7A patent/CN110713489B/zh active Active
- 2015-03-12 UA UAA201610495A patent/UA119667C2/uk unknown
- 2015-03-12 DK DK15711451.3T patent/DK3119772T3/da active
- 2015-03-12 KR KR1020167029202A patent/KR102431017B1/ko active Active
- 2015-03-12 US US15/125,599 patent/US20170008896A1/en not_active Abandoned
- 2015-03-12 AP AP2016009373A patent/AP2016009373A0/en unknown
- 2015-03-12 WO PCT/EP2015/055237 patent/WO2015140054A1/en not_active Ceased
- 2015-03-12 SI SI201530823T patent/SI3119772T1/sl unknown
- 2015-03-12 EP EP15711451.3A patent/EP3119772B8/en active Active
- 2015-03-12 ES ES15711451T patent/ES2738416T3/es active Active
- 2015-03-12 US US15/027,518 patent/US9914735B2/en active Active
- 2015-03-12 RS RS20191047A patent/RS59110B1/sr unknown
- 2015-03-12 WO PCT/EP2015/055242 patent/WO2015140055A1/en not_active Ceased
- 2015-03-12 WO PCT/EP2015/055228 patent/WO2015140051A1/en not_active Ceased
- 2015-03-12 AU AU2015233654A patent/AU2015233654B2/en active Active
- 2015-03-12 LT LTEP15711451.3T patent/LT3119772T/lt unknown
- 2015-03-12 JP JP2016557602A patent/JP6535022B2/ja active Active
- 2015-03-12 SG SG11201607794QA patent/SG11201607794QA/en unknown
- 2015-03-12 JP JP2016557952A patent/JP6416275B2/ja active Active
- 2015-03-12 HU HUE15711451A patent/HUE046061T2/hu unknown
- 2015-03-12 MX MX2016011784A patent/MX2016011784A/es active IP Right Grant
- 2015-03-12 ME MEP-2019-222A patent/ME03472B/me unknown
- 2015-03-12 HR HRP20191364 patent/HRP20191364T1/hr unknown
- 2015-03-12 EP EP15711452.1A patent/EP3119765B1/en active Active
- 2015-03-12 PL PL15711451T patent/PL3119772T3/pl unknown
- 2015-03-12 PE PE2016001619A patent/PE20161427A1/es unknown
- 2015-03-12 PT PT15711451T patent/PT3119772T/pt unknown
- 2015-03-12 MY MYPI2016001423A patent/MY185837A/en unknown
- 2015-03-12 CN CN201910255696.5A patent/CN110183440B/zh active Active
- 2015-03-18 TW TW104108672A patent/TWI680967B/zh active
- 2015-03-18 AR ARP150100815A patent/AR099785A1/es active IP Right Grant
- 2015-03-19 UY UY0001036037A patent/UY36037A/es unknown
-
2016
- 2016-08-02 IL IL24705716A patent/IL247057B/en active IP Right Grant
- 2016-08-04 CL CL2016001963A patent/CL2016001963A1/es unknown
- 2016-09-14 PH PH12016501796A patent/PH12016501796A1/en unknown
-
2017
- 2017-11-20 US US15/817,435 patent/US20180072744A1/en not_active Abandoned
-
2019
- 2019-08-08 US US16/535,337 patent/US10947243B2/en active Active
- 2019-08-20 CY CY20191100888T patent/CY1121937T1/el unknown